PLGA microparticles with zero-order release of the labile anti-Parkinson drug apomorphine.
Identifieur interne : 000C85 ( Main/Merge ); précédent : 000C84; suivant : 000C86PLGA microparticles with zero-order release of the labile anti-Parkinson drug apomorphine.
Auteurs : C. Regnier-Delplace [France] ; O. Thillaye Du Boullay ; F. Siepmann ; B. Martin-Vaca ; N. Degrave ; P. Demonchaux ; O. Jentzer ; D. Bourissou ; J. SiepmannSource :
- International journal of pharmaceutics [ 1873-3476 ] ; 2013.
English descriptors
- KwdEn :
- Antiparkinson Agents (administration & dosage), Antiparkinson Agents (chemistry), Apomorphine (administration & dosage), Apomorphine (chemistry), Calorimetry, Differential Scanning, Drug Carriers (chemistry), Drug Compounding, Drug Stability, Freeze Drying, Hydrogen-Ion Concentration, Lactic Acid (chemistry), Microscopy, Electron, Scanning, Particle Size, Polyglycolic Acid (chemistry), Solubility, Surface Properties, X-Ray Diffraction.
- MESH :
- chemical , administration & dosage : Antiparkinson Agents, Apomorphine.
- chemical , chemistry : Antiparkinson Agents, Apomorphine, Drug Carriers, Lactic Acid, Polyglycolic Acid.
- Calorimetry, Differential Scanning, Drug Compounding, Drug Stability, Freeze Drying, Hydrogen-Ion Concentration, Microscopy, Electron, Scanning, Particle Size, Solubility, Surface Properties, X-Ray Diffraction.
Abstract
The treatment of patients suffering from advanced Parkinson's disease is highly challenging, because the efficacy of the "gold standard" levodopa declines with time. Co-administration of the dopamine receptor agonist apomorphine is beneficial, but difficult due to the poor oral bioavailability and short half-life of this drug. In order to overcome these restrictions, PLGA-based microparticles allowing for controlled parenteral delivery of this morphine derivative were prepared using (solid-in-)oil-in-water extraction/evaporation techniques. Particular attention was paid to minimize spontaneous oxidation of the labile drug and to optimize the key features of the microparticles, including encapsulation efficiency, initial burst release and particle size. Various formulation and processing parameters were adjusted in this respect. The systems were thoroughly characterized using SEM, EDX, DSC, laser diffraction, headspace-GC as well as in vitro drug release measurements in agitated flasks and flow-through cells. Importantly, apomorphine could effectively be protected against degradation during microparticle preparation and within the delivery systems upon exposure to phosphate buffer pH 7.4 (containing 0.2% ascorbic acid) at 37 °C: 90% intact drug was released at a constant rate during about 10d.
DOI: 10.1016/j.ijpharm.2013.01.008
PubMed: 23313920
Links toward previous steps (curation, corpus...)
- to stream PubMed, to step Corpus: 000769
- to stream PubMed, to step Curation: 000736
- to stream PubMed, to step Checkpoint: 000736
- to stream Ncbi, to step Merge: 001052
- to stream Ncbi, to step Curation: 001052
- to stream Ncbi, to step Checkpoint: 001052
Links to Exploration step
pubmed:23313920Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">PLGA microparticles with zero-order release of the labile anti-Parkinson drug apomorphine.</title><author><name sortKey="Regnier Delplace, C" sort="Regnier Delplace, C" uniqKey="Regnier Delplace C" first="C" last="Regnier-Delplace">C. Regnier-Delplace</name><affiliation wicri:level="3"><nlm:affiliation>University of Lille, College of Pharmacy, 3 Rue du Prof. Laguesse, 59006 Lille, France.</nlm:affiliation><country xml:lang="fr">France</country><wicri:regionArea>University of Lille, College of Pharmacy, 3 Rue du Prof. Laguesse, 59006 Lille</wicri:regionArea><placeName><region type="region" nuts="2">Hauts-de-France</region><region type="old region" nuts="2">Nord-Pas-de-Calais</region><settlement type="city">Lille</settlement></placeName></affiliation></author><author><name sortKey="Thillaye Du Boullay, O" sort="Thillaye Du Boullay, O" uniqKey="Thillaye Du Boullay O" first="O" last="Thillaye Du Boullay">O. Thillaye Du Boullay</name></author><author><name sortKey="Siepmann, F" sort="Siepmann, F" uniqKey="Siepmann F" first="F" last="Siepmann">F. Siepmann</name></author><author><name sortKey="Martin Vaca, B" sort="Martin Vaca, B" uniqKey="Martin Vaca B" first="B" last="Martin-Vaca">B. Martin-Vaca</name></author><author><name sortKey="Degrave, N" sort="Degrave, N" uniqKey="Degrave N" first="N" last="Degrave">N. Degrave</name></author><author><name sortKey="Demonchaux, P" sort="Demonchaux, P" uniqKey="Demonchaux P" first="P" last="Demonchaux">P. Demonchaux</name></author><author><name sortKey="Jentzer, O" sort="Jentzer, O" uniqKey="Jentzer O" first="O" last="Jentzer">O. Jentzer</name></author><author><name sortKey="Bourissou, D" sort="Bourissou, D" uniqKey="Bourissou D" first="D" last="Bourissou">D. Bourissou</name></author><author><name sortKey="Siepmann, J" sort="Siepmann, J" uniqKey="Siepmann J" first="J" last="Siepmann">J. Siepmann</name></author></titleStmt><publicationStmt><idno type="wicri:source">PubMed</idno><date when="2013">2013</date><idno type="RBID">pubmed:23313920</idno><idno type="pmid">23313920</idno><idno type="doi">10.1016/j.ijpharm.2013.01.008</idno><idno type="wicri:Area/PubMed/Corpus">000769</idno><idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Corpus" wicri:corpus="PubMed">000769</idno><idno type="wicri:Area/PubMed/Curation">000736</idno><idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Curation">000736</idno><idno type="wicri:Area/PubMed/Checkpoint">000736</idno><idno type="wicri:explorRef" wicri:stream="Checkpoint" wicri:step="PubMed">000736</idno><idno type="wicri:Area/Ncbi/Merge">001052</idno><idno type="wicri:Area/Ncbi/Curation">001052</idno><idno type="wicri:Area/Ncbi/Checkpoint">001052</idno><idno type="wicri:Area/Main/Merge">000C85</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en">PLGA microparticles with zero-order release of the labile anti-Parkinson drug apomorphine.</title><author><name sortKey="Regnier Delplace, C" sort="Regnier Delplace, C" uniqKey="Regnier Delplace C" first="C" last="Regnier-Delplace">C. Regnier-Delplace</name><affiliation wicri:level="3"><nlm:affiliation>University of Lille, College of Pharmacy, 3 Rue du Prof. Laguesse, 59006 Lille, France.</nlm:affiliation><country xml:lang="fr">France</country><wicri:regionArea>University of Lille, College of Pharmacy, 3 Rue du Prof. Laguesse, 59006 Lille</wicri:regionArea><placeName><region type="region" nuts="2">Hauts-de-France</region><region type="old region" nuts="2">Nord-Pas-de-Calais</region><settlement type="city">Lille</settlement></placeName></affiliation></author><author><name sortKey="Thillaye Du Boullay, O" sort="Thillaye Du Boullay, O" uniqKey="Thillaye Du Boullay O" first="O" last="Thillaye Du Boullay">O. Thillaye Du Boullay</name></author><author><name sortKey="Siepmann, F" sort="Siepmann, F" uniqKey="Siepmann F" first="F" last="Siepmann">F. Siepmann</name></author><author><name sortKey="Martin Vaca, B" sort="Martin Vaca, B" uniqKey="Martin Vaca B" first="B" last="Martin-Vaca">B. Martin-Vaca</name></author><author><name sortKey="Degrave, N" sort="Degrave, N" uniqKey="Degrave N" first="N" last="Degrave">N. Degrave</name></author><author><name sortKey="Demonchaux, P" sort="Demonchaux, P" uniqKey="Demonchaux P" first="P" last="Demonchaux">P. Demonchaux</name></author><author><name sortKey="Jentzer, O" sort="Jentzer, O" uniqKey="Jentzer O" first="O" last="Jentzer">O. Jentzer</name></author><author><name sortKey="Bourissou, D" sort="Bourissou, D" uniqKey="Bourissou D" first="D" last="Bourissou">D. Bourissou</name></author><author><name sortKey="Siepmann, J" sort="Siepmann, J" uniqKey="Siepmann J" first="J" last="Siepmann">J. Siepmann</name></author></analytic><series><title level="j">International journal of pharmaceutics</title><idno type="eISSN">1873-3476</idno><imprint><date when="2013" type="published">2013</date></imprint></series></biblStruct></sourceDesc></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Antiparkinson Agents (administration & dosage)</term><term>Antiparkinson Agents (chemistry)</term><term>Apomorphine (administration & dosage)</term><term>Apomorphine (chemistry)</term><term>Calorimetry, Differential Scanning</term><term>Drug Carriers (chemistry)</term><term>Drug Compounding</term><term>Drug Stability</term><term>Freeze Drying</term><term>Hydrogen-Ion Concentration</term><term>Lactic Acid (chemistry)</term><term>Microscopy, Electron, Scanning</term><term>Particle Size</term><term>Polyglycolic Acid (chemistry)</term><term>Solubility</term><term>Surface Properties</term><term>X-Ray Diffraction</term></keywords><keywords scheme="MESH" type="chemical" qualifier="administration & dosage" xml:lang="en"><term>Antiparkinson Agents</term><term>Apomorphine</term></keywords><keywords scheme="MESH" type="chemical" qualifier="chemistry" xml:lang="en"><term>Antiparkinson Agents</term><term>Apomorphine</term><term>Drug Carriers</term><term>Lactic Acid</term><term>Polyglycolic Acid</term></keywords><keywords scheme="MESH" xml:lang="en"><term>Calorimetry, Differential Scanning</term><term>Drug Compounding</term><term>Drug Stability</term><term>Freeze Drying</term><term>Hydrogen-Ion Concentration</term><term>Microscopy, Electron, Scanning</term><term>Particle Size</term><term>Solubility</term><term>Surface Properties</term><term>X-Ray Diffraction</term></keywords></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">The treatment of patients suffering from advanced Parkinson's disease is highly challenging, because the efficacy of the "gold standard" levodopa declines with time. Co-administration of the dopamine receptor agonist apomorphine is beneficial, but difficult due to the poor oral bioavailability and short half-life of this drug. In order to overcome these restrictions, PLGA-based microparticles allowing for controlled parenteral delivery of this morphine derivative were prepared using (solid-in-)oil-in-water extraction/evaporation techniques. Particular attention was paid to minimize spontaneous oxidation of the labile drug and to optimize the key features of the microparticles, including encapsulation efficiency, initial burst release and particle size. Various formulation and processing parameters were adjusted in this respect. The systems were thoroughly characterized using SEM, EDX, DSC, laser diffraction, headspace-GC as well as in vitro drug release measurements in agitated flasks and flow-through cells. Importantly, apomorphine could effectively be protected against degradation during microparticle preparation and within the delivery systems upon exposure to phosphate buffer pH 7.4 (containing 0.2% ascorbic acid) at 37 °C: 90% intact drug was released at a constant rate during about 10d.</div></front></TEI></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Sante/explor/ParkinsonFranceV1/Data/Main/Merge
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000C85 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Main/Merge/biblio.hfd -nk 000C85 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Wicri/Sante
|area= ParkinsonFranceV1
|flux= Main
|étape= Merge
|type= RBID
|clé= pubmed:23313920
|texte= PLGA microparticles with zero-order release of the labile anti-Parkinson drug apomorphine.
}}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/Main/Merge/RBID.i -Sk "pubmed:23313920" \
| HfdSelect -Kh $EXPLOR_AREA/Data/Main/Merge/biblio.hfd \
| NlmPubMed2Wicri -a ParkinsonFranceV1
| This area was generated with Dilib version V0.6.29. |  |